The i-Technology Media!
Register | Log in
   
 
.NET  ·  AJAX  ·  CLOUD  ·  ECLIPSE  ·  FLEX  ·  OPEN WEB  ·  iPHONE  ·  JAVA  ·  LINUX  ·  OPEN SOURCE  ·  ORACLE  ·  PBDJ  ·  SEARCH  ·  SILVERLIGHT  ·  SOA  ·  VIRTUALIZATION  ·  WEB 2.0  ·  WIRELESS  ·  XML
Comments
Google Wave Invitation Giveaway
By Aditya Banerjee
Timo Hirvonen wrote: I would really appreciate an invitation. Been desperately trying to find one :) timo [dot] hirvonen [at] gmail [dot]com
Nov. 27, 2009 11:13 AM EST
Cloud Expo on Google News
Did you read today's front page stories & breaking news?


2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts

2009 East
GOLD SPONSORS:
CA
Get Your Transactions Under Control: SOA Performance Management
Software AG
Performance Driven Adoption: The Secret to Advancing SOA
Intel
The Evolving SOA Appliance: 3 Game-Changing Innovations
SILVER SPONSOR:
Denodo
Data Mashups: Deliver Your Project Faster with Virtualized Data Services Across Internal & External Sources
POWER PANELS:
The Business Value of Service Orientation
Driving Profitability Through User Experience
Click For 2008 West
Event Webcasts
Live Google News by SYS-CON!
Top Three Links You Must Click On


From the Wires
Sigma-tau Submits Marketing Authorization Application to EMEA for a Novel Anti-Malarial
- An Innovative Fixed-Dose Combination Therapy, With a Very Simple Dosing Regimen, for Combating a Disease That Accounts for 250 Million Cases Worldwide Per Year and Causes 880,000 Deaths, Especially of Children Under 5 in Sub-Saharan Africa

By: PR Newswire
Jul. 6, 2009 03:00 AM

ROME, July 6 /PRNewswire/ -- Sigma-tau Industrie Farmaceutiche Riunite S.p.A. (sigma-tau) has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for Eurartesim(R) (dihydroartemisinin/piperaquine), a novel fixed-dose Artemisinin-based Combination Therapy or ACT. Eurartesim(R) is highly effective against uncomplicated malaria in adults and children, has a simple dosing regimen (only 3 administrations over 3 days) and has been shown to offer greater protection against new infections than other ACTs, for at least 2 months after treatment.

In 2008, malaria was endemic in 109 countries, 45 of which were in Africa. It afflicts up to 250 million people worldwide every year and causes around 880,000 deaths mainly in sub-Saharan Africa, over 85% of whom are children under 5. Currently, only a handful of antimalarials remain effective as treatment. Eurartesim(R) will be a welcome addition to the arsenal of malaria drugs and, once approved and marketed, it could help to save the lives of hundreds of thousands of young African children.

This new ACT is the first product of a collaboration between sigma-tau and Medicines for Malaria Venture (MMV), an international not-for-profit organisation. Developed to high international standards, this new ACT meets WHO clinical treatment recommendations, as it combines two active antimalarial ingredients in a single tablet: the highly potent artemisinin-derivative (dihydroartemisinin) with a second antimalarial (piperaquine) which protects the first one against the emergence of resistance.

Eurartesim(R) has already received the Orphan Drug Designation by both European and US regulatory authorities. After receiving approval from the EMEA, sigma-tau also intends to consider filing for marketing authorization in the US. Stringent regulatory approval, guarantee of highest international standards respect, is a precondition for approval in Africa and, once this precondition is met the dossier will be submitted to selected African countries with the support of Pfizer, sigma-tau's partner to commercialize the drug in Africa's private sector in order to maximize Eurartesim's potential to reach as many patients as possible.

The MAA is supported by data from large clinical trials that involved over 2,700 patients in Africa (Burkina Faso, Zambia, Kenya, Mozambique and Uganda) and Asia (Thailand, India and Laos). 1,600 of these were children under 5, all with uncomplicated malaria caused by Plasmodium falciparum, the most widespread and dangerous malaria parasite. The studies were designed to compare the safety and efficacy of the combination of dihydroartemisinin and piperaquine (DHA/PQP) to the ACTs artemether/lumefantrine (in Africa) and artesunate+mefloquine (in Asia).

Results from both studies show that Eurartesim(R) treats malaria as rapidly and effectively as the other ACTs. It has also been shown to offer significant protection from new infections in many cases for about 2 months. In addition, it features a simple schedule: a patient weighing 60 kg needs to take a total of 9 tablets over 3 days compared to the 14 to 24 tablets with other antimalarials. Fever and parasites disappear after only 2-3 days from start of treatment.

"sigma-tau is committed to the development of new therapies that will benefit people living with tropical diseases like malaria - said Dr. Claudio Cavazza, President of sigma-tau - We agree with the WHO's call to pharmaceutical companies to develop new antimalarials according to the highest international quality standards. We make available our industrial know-how for allowing drug distribution, at a sustainable price, in those countries where malaria still kills unacceptable numbers of people, sharing the aim of the main industrialised countries taking part in G8 scheduled in L'Aquila. The submission for this innovative ACT brings us one step closer to providing a potent treatment to vulnerable populations in malaria-endemic countries where malaria has a tremendous health and socio-economic impact, as well as to European and American citizens travelling to those countries for business or tourism."

"The submission of Eurartesim(R) to the EMEA is a landmark event and the culmination of several years' productive collaboration between sigma-tau and Medicines for Malaria Venture - said Dr Chris Hentschel, President and CEO of Medicines for Malaria Venture - Head-to-head studies carried out to internationally approved standards have shown that this ACT is at least as safe and efficacious as two other well-known ACTs. Its addition to the therapeutic arsenal will give more choice to health policy makers and caregivers in malaria-endemic countries to choose the right medicine for their patients."

Published Jul. 6, 2009— Reads 117
Copyright © 2009 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers

ADS BY GOOGLE

Breaking Java News
Homeland Uranium Inc. Reprices Options
South American Silver Corp. Completes $2.78 Million Financing
Stone Resources Limited Announces Resignation of Directors
L.A.'s West 3rd Street to Launch Public Valet Service Tomorrow
Lorus Therapeutics Raises $2.46 Million in Equity Financing
Cagim Announces Increase in Results for Second Quarter of Fiscal Year 2009
Chai-Na-Ta Corp. Reports 2009 Third Quarter Results
Statement of Condolence-Nelson Leeson, President of the Nisga'a Lisims Government
T.G.I. Friday's(R) Restaurants Announce Gift Card Giveaway
Media Advisory: New National Research Council, University of Ottawa Laboratory Home to Canada's Fastest X-Ray Laser

ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS:   |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  Cloud Computing Conference & Expo  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.
 
close this window